| Literature DB >> 36015329 |
Yubiao Cao1,2, Zhuowen Chen1,2, Liangliang Sun1,2, Yameng Lin1,2, Ye Yang1,2, Xiuming Cui1,2, Chengxiao Wang1,2.
Abstract
Herb polysaccharides (HPS) have been studied extensively for their healthcare applications. Though the toxicity was not fully clarified, HPS were widely accepted for their biodegradability and biocompatibility. In addition, as carbohydrate polymers with a unique chemical composition, molecular weight, and functional group profile, HPS can be conjugated, cross-linked, and functionally modified. Thus, they are great candidates for the fabrication of drug delivery systems (DDS). HPS-based DDS (HPS-DDS) can bypass phagocytosis by the reticuloendothelial system, prevent the degradation of biomolecules, and increase the bioavailability of small molecules, thus exerting therapeutic effects. In this review, we focus on the application of HPS as components of immunoregulatory DDS. We summarize the principles governing the fabrication of HPS-DDS, including nanoparticles, micelles, liposomes, microemulsions, hydrogels, and microneedles. In addition, we discuss the role of HPS in DDS for immunotherapy. This comprehensive review provides valuable insights that could guide the design of effective HPS-DDS.Entities:
Keywords: application; drug delivery system; herb polysaccharides; immune regulation; structure modification
Year: 2022 PMID: 36015329 PMCID: PMC9414761 DOI: 10.3390/pharmaceutics14081703
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Summary of herb polysaccharides and their bioactivities.
| Herb | Molecular Weight | Monosaccharide Composition and Proportion of Monosaccharide | Main Types of Glycosidic Bonds | Pharmacological | References |
|---|---|---|---|---|---|
| Bletilla striata polysaccharides | 8.354 × 104 Da | Man and Glc in the ratio of 4.0:1.0 | Backbone composed of β-1,4-linked Manp | Immunomodulatory | [ |
| 1.46 × 105 Da | Man and Glc in the ratio of 2.4:1.0 | α-Man and β-Glc residues | Anti-inflammatory | [ | |
| Mw:3.73 × 105 g/mol | Man and Glc in the ratio of 2.946:1 | Composed of 1,4-linked Glcp | Anti-inflammatory | [ | |
| 2.35 × 105 Da | Man, Glc, and Gal in the ratio of 9:2.6:1.0 | Composed of 1,4-linked Manp and 1,4-linked Glcp in a molar ratio of 2:1 | Immunomodulatory | [ | |
| Angelica sinensis polysaccharides | 1.0 × 105 Da | Glc | α-(1→6)-glucan | Immunomodulatory | [ |
| 44,000 Da | arabinose and galactose, as well as xylose, rhamnose and mannose | 1,5 linked, galactose containing 1,4 and 1,4,6 linked units, xylose 1,4 linked, rhamnose 1,2 linked, and terminal mannose | [ | ||
| American Ginseng polysaccharides | Arabinose, rhamnose, mannose, glucose, and glucose acid | Immunomodulatory | [ | ||
| 3.1 kDa | Glucose (Glc) and galactose (Gal) in a molar ratio of 1:1.15 | Anti-inflammatory | [ | ||
| Astragalus membranaceus | Glucose, in addition to rhamnose, galactose, arabinose, xylose, mannose, glucuronic acid, and galacturonic acid | Immunoregulatory, antitumor, anti-inflammatory, and antiviral | [ | ||
| Lycium barbarum L. polysaccharides | 4.2 × 104 Da | Glucose, mannose, and galactose | (1→3)-linked α- | Anti-inflammatory | [ |
| Yam polysaccharides | 4.2 × 104 Da | Glc:Man:Gal = 1:0.37:0.11 | (1→3)-α-Glucopyranose as the main chain and β-galactopyranose-[(1→2)-α-mannopyranose]3-(1→2)-α-mannopyranose-(1→6) as the side chain | Immunomodulatory | [ |
Summary of HPS-DDS.
| Type of Dosage Form | Polysaccharides | Drug | Curing Disease | Preparation Method | The Role of HPS in DDS | Aimed Cells | Size (nm) | Zeta (mV) | Refs |
|---|---|---|---|---|---|---|---|---|---|
| HPS nanoparticles | Immunoregulation; Reduce skin cancer | Self-aggregation; Polymer encapsulation | Immunologic adjuvant; Macromolecular drugs | Macrophages | 180 ± 10; 20 | [ | |||
| HPS–polymeric nanoparticles | Ramulus mori polysaccharides | Inflammatory bowel disease; Colitis | Polymer encapsulation | Macromolecular drugs | Macrophages | 205.6 ± 4.26; | −31.7 ± 1.097 | [ | |
| Inulin | Antigens | Stimulated the Th2 type immune response. | Polymer encapsulation | Immunologic adjuvant | Antigen presenting cells | 1.5 ± 0.12 | [ | ||
| Aloe polysaccharides | Angular leaf spot | Polymer encapsulation | Macromolecular drugs | 644.00 ± 0.52; 243.20 ± 0.22 | [ | ||||
| Chinese yam polysaccharides | Ovalbumin | Strengthen immune responses | Polymer encapsulation; Covalent link | Immunologic adjuvant | CD3(+)CD4(+) T cells CD3(+)CD8(+) T cells | 200 | [ | ||
| Ovalbumin; Inactivated H9N2 | Induce strong and long-term immune responses; H9N2 influenza | Polymer encapsulation | Macromolecular drugs; Immunologic adjuvant | CD4(+)/CD8(+) T cells | 225.2; | −11.27; 47.8 ± 0.24 | [ | ||
| Ovalbumin | Improve immune responses | Polymer encapsulation | Immunologic adjuvant | Macrophages and lymphocytes | 141.4; 156.4; 175.9 | −17.9 ± 1.29; −26.9 ± 2.76; 31.4 ± 2.18 | [ | ||
| Micelles | Chloroquine | Cancer immunotherapy | Self-aggregation | Targeting; Immunologic adjuvant | 4T1-M2 macrophages | 120 | −35 | [ | |
| Curcumin; | Acute alcoholic liver damage; Liver cancer | Polymer encapsulation; Covalent link | Drug carrier; Targeting | HepG2 | 208.4; 228 | −20; −17 | [ | ||
| Doxorubicin; Docetaxel; Silymarin; Let-7b; Alendronate | Antitumor; Liver diseases; Suppressive tumor microenvironment; Suppressed tumor progression | Crosslinking; Covalent link | Drug carrier; Targeting; Stabilizer | HepG2, HeLa, SW480, and MCF-7 | 125.30 ± 1.89; 96.27 ± 1.21; 96.54 ± 5.27; 99.21 ± 3.83; 121.61 ± 9.81; 125.30 ± 1.89; 120; 67 | −26.92 ± 0.18; −35.66 ± 0.28; −35.46 ± 0.10; −34.76 ± 0.22; −28.37 ± 0.12; −26.92 ± 0.18; −13; −19 | [ | ||
| Inactivated Bb | Crosslinking; Covalent link; Self-aggregation | Immunologic adjuvant | Dendritic cells (DCs) | [ | |||||
| Inhibited the growth of tumor | Self-aggregation | Immunologic adjuvant | Dendritic cells (DC) | 138 ± 5 | −12.4 ± 0.3 | [ | |||
| Polysaccharide-drug conjugations | Platinum-based; Doxorubicin | Anticancer | Covalent link | Targeting; Immunologic adjuvant; Stabilizer; Immunologic adjuvant | A549 (human lung cancer cell line) | 273.3 | −25.6 | [ | |
| 5-fluorouracil | Antitumor | Covalent link | Targeting; Immunologic adjuvant | Splenocytes and peritoneal macrophages | 124.7 | [ | |||
| Polysaccharide-Metal | AgNPs | Antibacterial | Crosslinking | Stabilizer | 24.5-83.2 | −36 | [ | ||
| AgNPs; | Antibacterial; Antitumor and immunoregulation | Crosslinking | Stabilizer; Stabilizer; Immunologic adjuvant | Dendritic cells/T cells | 65.08; 25.38 | −28.33 | [ | ||
| ZnNPs | Anti-diabetes | Crosslinking; Polymer encapsulation | Stabilizer; Immunologic adjuvant | [ | |||||
| AgNPs | Anticancer, Antifungal and Preservative | Crosslinking | Stabilizer; Solubilizer | 8–20 | −14.2 | [ | |||
| Tamarind polysaccharides | AgNPs; | Antibacterial; Anticancer and immunomodulatory | Crosslinking; Polymer encapsulation | Stabilizer; Immunologic adjuvant | 44–86; 30–40; 20 | −36.7 | [ | ||
| Farfarae Flos polysaccharides | AgNPs | Anticancer | Self-aggregation | Stabilizer | HT29 cells | 4–25 | −17.1 | [ | |
| AgNPs | Antioxidation or antimicrobial | Self-aggregation | Stabilizer | 25–35 | −25.23 | [ | |||
| AgNPs | Antibacterial | Self-aggregation | Stabilizer | [ | |||||
| AgNPs | Wound healing | Self-aggregation | Stabilizer | 17.6 | −25.6 | [ | |||
| Apple polysaccharides | AuNPs | Anti-diabetes | Polymer encapsulation | Stabilizer | 124 ± 8.55 | −10.5 ± 0.54 | [ | ||
| HPS-inorganic nanoparticles | SeNPs | Anticancer | Covalent link; Crosslinking | Solubilizer; Targeting | Glioma cells | 123 | −24.0 | [ | |
| Citrus limon polysaccharide | SeNPs | Antitumor | Covalent link | Stabilizer | 85.35; 79.67; 90.14 | −9.44; −7.52; −6.87 | [ | ||
| SeNPs | Antioxidation | Covalent link | Stabilizer | 105 | −34.9 | [ | |||
| SeNPs; Chitosan | Antioxidation, enhance the proliferation of T-lymphocytes and Inhibit HepG2 cells proliferation; Exhibited high permeation through intestinal enterocytes | Covalent link; Self-aggregation; Electrostatic adsorption | Solubilizer | HepG2 cells | 478.1; 100–150 | −20.39; +16 | [ | ||
| SeNPs | Antioxidation | Covalent link | Immunologic adjuvant; stabilizer | 50 | [ | ||||
| SeNPs | Anti-fatigue; Antitumor; | Covalent link | Stabilizer; Solubilizer | Lens epithelial cells | 105.4; 111.5–117; 150–200; 83–160 | −37; −24.1 | [ | ||
| SeNPs | Inhibit the proliferation and promote apoptosis of HepG2 cells | Covalent link | Solubilizer; Stabilizer | HepG2 cells | 75 | [ | |||
| Dandelion polysaccharides | SeNPs | Anti-tumor | Covalent link; Polymer encapsulation | Immunologic adjuvant; stabilizer; | HepG2, A549, and HeLa | 50 | [ | ||
| Other HPS based NPs | Curcumin | Anticancer; Antioxidation and antibacterial | Physical mixture; Crosslinking | Solubilizer; Targeting; Drug carrier | MCF7 human breast cancer cell line | 250–300; 200 | [ | ||
| Tamarind Gum polysaccharides | Simvastatin | Antitumor | Covalent link; Electrostatic adsorption | Solubilizer; Targeting; Stabilizer | Human breast cancer cell line | 53.3–383.1 | [ | ||
| Hydrogel | Lactobacillus plantarum probiotics | Skin lesions; Bleeding disorders; Wound infection | Covalent link; Crosslinking | Immunologic adjuvant; Stabilizer; | L929 cells | [ | |||
| 5-fluorouracil | Antitumor | Crosslinking | Immunologic adjuvant; stabilizer; | [ | |||||
| Silver nanoparticle | Wound infection | Crosslinking | Stabilizer | [ | |||||
| Microneedle | Doxorubicin and 5-fluorouracil | Antitumor | Physical mixture | Drug carriers; Immunologic adjuvant | Skin dendritic cell | [ | |||
| Ovalbumin; Triamcinolone acetonide and verapamil | Infectious disease; Hypertrophic scars | Physical mixture | Stabilizer; Drug carriers; Immunologic adjuvant | [ | |||||
| HPS-based liposome | Polymer encapsulation | [ | |||||||
| Immunological and adjuvanticity against PCV2 in vivo | Polymer encapsulation | Immunologic adjuvant; Macromolecular drugs | Spleen cells, macrophagesCD4(+)/CD8(+) T cells | 120.7 ± 0.84 | [ | ||||
| HPS-Emulsion | Polymer encapsulation | Emulsifier | 1500 | −30 | [ | ||||
| Polymer encapsulation | Emulsifier | 1160–2790 | −35.83−−19.00 | [ | |||||
| Soy protein | Emulsion digestion in the gastrointestinal tract | Polymer encapsulation | Stabilizer | 835 | −129.76 | [ |
Figure 1Fabrication and application of HPS amphiphilic derivatives.
Figure 2Fabrication and application of HPS-MNPs. (↑: Increase; ↓: Decrease).
Figure 3Fabrication and applications of HPS-based DMNs.